This study aimed to detect novel mesenchymal stem cell peptides/biomarkers of bronchopulmonary dysplasia (BPD) in the tracheal aspirate fluid (TAF) of preterm infants.
STUDY DESIGN:
Participants included infants less than 32 weeks’ gestational age or birth weight under 1500 grams who required endotracheal intubation and mechanical ventilation within first 24 hours of life. TAF sample collection was performed at the time of the first clinically indicated routine suctioning. Standardization curves for human levels of osteopontin (Opn), macrophage colony stimulating factor 1 (Csf1), transforming growth factor beta 1 (TGF-β1), and secretory immunoglobulin A (sIgA) were generated for 15 enrolled participants.
RESULTS:
We demonstrated that stem cell biomarkers are secreted into the TAF of preterm infants and their concentrations can be easily measured during the first week of life.
CONCLUSIONS:
Further studies are warranted to determine a causal relationship between these biomarkers and BPD development and severity.
JobeAH, BancalariE. Bronchopulmonary dysplasia. Am J Respir Crit Care Med2001;163(7):1723–9.
2.
ShennanAT, DunnMS, OhlssonA, LennoxK, HoskinsEM. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics1988;82(4):527–32.
3.
EhrenkranzRA, WalshMC, VohrBR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics2005;116(6):1353–60.
4.
BancalariE, ClaureN, SosenkoIR. Bronchopulmonary dysplasia: Changes in pathogenesis, epidemiology and definition. Semin Neonatol2003;8(1):63–71.
5.
LeCras TD, KimDH, MarkhamNE, AbmanAS. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver’s altitude. Am J Physiol Lung Cell Mol PhysiolL2000;279(2):283–91.
6.
FanaroffAA, HackM, WalshMC. The NICHD neonatal research network: Changes in practice and outcomes during the first 15 years. Semin Perinatol2003;27(4):281–7.
7.
SingerL, YamashitaT, LilienL, CollinM, BaleyJ. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics1997;100(6):987–93.
8.
MajnemerA, RileyP, ShevellM, BirnbaumR, GreenstoneH, CoatesAL. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol2000;42(1):53–60.
9.
AndersonPJ, DoyleLW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol2006;30(4):227–32.
10.
KorhonenP, KoivistoAM, IkonenS, LaippalaP, TammelaO. Very low birthweight, bronchopulmonary dysplasia and health in early childhood. Acta Paediatr1999;88(12):1385–91.
BavejaR, ChristouH. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol2006;30(4):209–18.
13.
FarhathS, HeZ, NakhlaT, et al. Pepsin, a marker of gastric contents, is increased in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatrics2008;121(2):e253–9.
14.
KojimaT, SasaiM, KobayashiY. Increased soluble ICAM-1 in tracheal aspirates of infants with bronchopulmonary dysplasia. Lancet 3421993;342(8878):1023–4.
15.
LassusP, RistimakiA, YlikorkalaO, ViinikkaL, AnderssonS. Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med1999;159(5 Pt 1):1429–33.
16.
DananC, FrancoML, JarreauPH, et al. High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. Am J Respir Crit Care Med2002;165(10):1384–7.
17.
ChoiCW, KimBI, KimHS, ParkJD, ChoiJH, SonDW. Increase of interleukin-6 in tracheal aspirate at birth: A predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr2006;95(1):38–43.
18.
CederqvistK, SirenV, PetajaJ, VaheriA, HaglundC, AnderssonS. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome. Pediatrics2006;117(4):1226–34.
19.
ShimotakeTK, IzharFM, RumillaK, et al. Interleukin (IL)-1 beta in tracheal aspirates from premature infants induces airway epithelial cell IL-8 expression via an NF-kappa B dependent pathway. Pediatr Res2004;56(6):907–13.
20.
AghaiZH, CamachoJ, SaslowJG, et al. Impact of histological chorioamnionitis on tracheal aspirate cytokines in premature infants. Am J Perinatol2012;29(7):567–72.
21.
OeiJ, LuiK, WangH, HenryR. Decreased interleukin-10 in tracheal aspirates from preterm infants developing chronic lung disease. Acta Paediatr2002;91(11):1194–9.
22.
KotechaSCytokines in chronic lung disease of prematurity. Eur J Pediatr1996;155(Suppl 2):S14–7.
23.
KotechaS, WilsonL, WangooA, SilvermanM, ShawRJ. Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res1996;40(2):250–6.
24.
MadtesDK, RubenfeldG, KlimaLD, et al. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med1998;158(2):424–30.
25.
NakanishiH, SugiuraT, StreisandJB, LonningSM, RobertsJDJr. TGF-beta-neutralizing antibodies improve pulmonary alveologenesis and vasculogenesis in the injured newborn lung.
Am J Physiol Lung Cell Mol Physiol2007;293(1):151–61.
26.
LecartC, CayabyabR, BuckleyS, et al. Bioactive transforming growth factor-beta in the lungs of extremely low birthweight neonates predicts the need for home oxygen supplementation. Biol Neonate2000;77(4):217–23.
PopovaAP, BozykPD, BentleyJK, et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatricse2010;126(5):1127–33.
29.
PopovaAP, BozykPD, GoldsmithAM, et al. Autocrine production of TGF-beta1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol2010;298(6):L735–43.
30.
PopovaAP, CuiTX, KacirotiN, et al. Tracheal aspirate levels of the matricellular protein SPARC predict development of bronchopulmonary dysplasia. PLoS One2015;10(12):e0144122.
31.
O’ReillyM, ThebaudB. Using cell-based strategies to break the link between bronchopulmonary dysplasia and the development of chronic lung disease in later life. Pulm Med2013)874161.
32.
RamachandranS, SuguiharaC, DrummondS, et al. Bone marrow-derived c-kit+cells attenuate neonatal hyperoxia-induced lung injury. Cell Transplant2015;24(1):85–95.
33.
GrisafiD, PozzobonM, DedjaA, et al. Human amniotic fluid stem cells protect rat lungs exposed to moderate hyperoxia. Pediatr Pulmonol2013;48(11):1070–80.
34.
AhnSY, ChangYS, KimSY, et al. Long-term (postnatal day 70) outcome and safety of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells in neonatal hyperoxic lung injury. Yonsei Med J2013;54(2):416–24.
35.
ChangYS, ChoiSJ, AhnSY, et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One2013;8(1):e52419.
36.
HansmannG, Fernandez-GonzalezA, AslamM, et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ2012;2(2):170–81.
37.
AslamM, BavejaR, LiangOD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med2009;180(11):1122–30.
38.
KothariAN, ArffaML, ChangV, et al. Osteopontin-A Master Regulator of Epithelial-Mesenchymal transition. J Clin Med2016;5(4).
39.
PapaporfyriouA, LoukidesS, KostikasK, et al. Increased levels of osteopontin in sputum supernatant in patients with COPD. Chest2014;146(4):951–8.
40.
ZhangXF, LiuS, ZhouYJ, ZhuGF, FodaHD. Osteopontin protects against hyperoxia-induced lung injury by inhibiting nitric oxide synthases. Chin Med J (Engl)2010;123(7):929–35.
41.
WangKX, DenhardtDT. Osteopontin: Role in immune regulation and stress responses.
Cytokine Growth Factor Rev2008;19(5-6):333–45.
42.
DenhardtDT, GiachelliCM, RittlingSR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol2001;41:723–49.
43.
RittlingSR, ChambersAF. Role of osteopontin in tumour progression. Br J Cancer2004;90(10):1877–81.
44.
XanthouG, AlissafiT, SemitekolouMS, et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med2007;13(5):570–8.
45.
SimoesDC, XanthouG, PetrochilouK, PanoutsakopoulouV, RoussosC, GratziouC. Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in chronic asthma. Am J Respir Crit Care Med2009;179(10):894–902.
46.
SamitasK, ZervasE, VittorakisS, et al. Osteopontin expression and relation to disease severity in human asthma. Eur Respir J2011;37(2):331–41.
47.
SamitasK, ZervasE, PanoutsakopoulouV, GagaM. Letter to the editor–osteopontin levels in human asthma. J Int Med Res2011;39(6):2441–2.
48.
HubelK, DaleDC, LilesWC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: Current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis2002;185(10):1490–501.
49.
RoilidesE, SeinT, HolmesA, et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis1995;172(4):1028–34.
